Recombinant therapeutic antibodies and proteins are preferred over conventional drugs as they mimic natural proteins and antibodies in the human body to fight against diseases like cancer and autoimmune disorders. They have fewer side effects and are more specific and potent than conventional drugs.

The global Recombinant Therapeutic Antibodies And Proteins Market is estimated to be valued at US$ 185.95 Bn in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

Recombinant therapeutic antibodies and proteins market is witnessing increasing demand for biosimilar antibodies owing to their high efficiency and low costs. Biosimilar antibodies are complex protein therapeutics approved for marketing after demonstrating high similarity to an approved reference antibody product. Biosimilars are anticipated to capture sizeable market share due to their lower costs and thus higher accessibility to patients. For example, as most blockbuster antibodies goes off patent, availability of biosimilar versions help physicians provide better treatment options to more patients.

Segment Analysis
The global recombinant therapeutic antibodies and proteins market is segmented based on product, application, end user and region. By product, the monoclonal antibodies segment dominated the market in 2023 and is expected to continue its dominance over the forecast period. Monoclonal antibodies are preferred over other recombinant therapeutic proteins due to their high specificity and affinity towards disease-causing antigens.

Key Takeaways
The global recombinant therapeutic antibodies and proteins market is expected to witness high growth, exhibiting a CAGR of 12% over the forecast period, due to the increasing prevalence of chronic diseases such as cancer and autoimmune disorders.

Regional analysis
North America dominated the global market in 2023 and is expected to remain the largest market during the forecast period. The high healthcare spending and strong presence of key market players in the US drive the North America market. Asia Pacific is expected to witness the fastest growth over the forecast period supported by growing healthcare infrastructure and increasing healthcare spending in emerging economies like China and India.

Key players
Key players operating in the recombinant therapeutic antibodies and proteins market are Roche, Johnson & Johnson, Novartis, Amgen. Roche dominates the global market with its wide portfolio of blockbuster monoclonal antibodies like Avastin, Herceptin, and MabThera. Novartis and Amgen also have a sizable presence in the market with their biosimilars and novel recombinant proteins.

For more details on the report, Read-

https://perfectinsights.blogspot.com/2023/12/the-recombinant-therapeutic-antibodies.html